Experimental Biology and Medicine
June 1, 1958
E. Costa, G. Zetler
7 citations
10 γ/kg i.p. of LSD potentiate the adrenal ascorbic acid depletion caused in rats by 25 γ/kg i.p. of epinephrine, 40 γ/kg i.p. of BOL are ineffective in this respect. 30 γ/kg i.p. of both serotonin and bufotenin potentiate the effects of epinephrine (25 γ/kg i.p.). The threshold doses of bufotenin and serotonin enhancing the epinephrine induced contractions of cat's nictitating membrane were...
A M A Archives of Neurology & Psychiatry
December 1, 1957
Lincoln D. Clark
19 citations
One consequence of the recent interest in psychotomimetic drugs has been a search for pharmacological agents that will "block" drug-induced psychological disturbances and hallucinations. Fabing1reported that azacyclonol (Frenquel) in small doses prevented the occurrence of lysergic acid diethylamide (LSD-25) "psychoses" in man, although one of us (L. D. C.) was unable to verify this...
Journal of Pharmacy and Pharmacology
September 1, 1957
E Rothlin
64 citations
Journal Article Pharmacology of Lysergic Acid Diethylamide and Some of Its Related CompoundS Get access E Rothlin E Rothlin Professor of the University of Basle, Sonnenweg 6, Basle Search for other works by this author on: Oxford Academic Google Scholar Journal of Pharmacy and Pharmacology, Volume 9, Issue 1, September 1957, Pages 569–587, https://doi.org/10.1111/j.2042-7158.1957.tb12312.x...
Archives of Neurology And Psychiatry
1956
Edward V. Evarts
52 citations
INTRODUCTION Bufotenine (5 -hydroxy -3 -[2- dimethyl-aminoethyl]-indole) is the N-dimethyl derivative of the vasoconstrictor substance serotonin (5-hydroxytryptamine). It was first synthesized by Wieland in 1934. Raymond-Hamet found that intravenous injection of bufotenine caused transient elevation of blood pressure and apnea, followed by tachypnea, in anesthetized dogs.* To date, however,...
A M A Archives of Neurology & Psychiatry
1956
Bert E. Schwarz
49 citations
Feldberg and Sherwood's* previous studies of the behavior of cats after the intraventricular injection of various drugs opened up a new method of investigation. By this technique they showed that drugs injected into this area of high pharmacologic sensitivity could evoke various complex behavioral responses and conditions resembling sleep, anesthesia, profound muscular weakness, catatonia, and...
The Journal of Nervous and Mental Disease
February 1, 1954
Harry H. Pennes
48 citations
* From the Department of Experimental Psychiatry (Paul H. Hoch, M.D.), New York State Psychiatric Institute.
Journal of Addictions Nursing
Deana Goldin, Deborah Salani
2 citations
Ayahuasca is a pan-Amazonian botanical hallucinogenic decoction made from a mixture of the bark of the Banisteriopsis caapi plant, containing a monoamine oxidase inhibitor, and Psychotria viridis (Rubiaceae) or Diplopterys cabrerana shrubs containing a serotonergic 2A receptor agonist, N,N-dimethyltryptamine, a powerful psychoactive substance. Ayahuasca is a traditional psychoactive sacrament...
Journal of Clinical Psychopharmacology
Vivian Kim, Scott M Wilson, Mary E Woesner
3 citations
Following a decades-long decline in psychedelic research resulting from social, political, and legislative factors, there has been greatly renewed interest in these compounds' ability to treat psychiatric disorders. Classic psychedelics, encompassing both natural and synthetic psychoactive compounds, are characterized by their action as agonists or partial agonists of serotonin...
Clinical Neuropharmacology
Jiancheng Qiu, Yifei Gong, Xiucui Zhang et al.
4 citations
This study was aimed to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) on depressive symptoms, brain potential, and neuroimmunoinflammatory factors in patients with depression. Sixty-four eligible patients according to the inclusion criteria were randomly divided into the control group and the observation group, with 32 patients in each group. The control group...
Journal of Clinical Psychopharmacology
Giordano Novak Rossi, Juliana Mendes Rocha, Flávia L. Osório et al.
12 citations
Serotonergic hallucinogens and cannabinoids may alter the recognition of emotions in facial expressions (REFE). Cannabidiol (CBD) attenuates the psychoactive effects of the cannabinoid-1 agonist tetrahydrocannabinol. Ayahuasca is a dimethyltryptamine-containing hallucinogenic decoction. It is unknown if CBD may moderate and attenuate the effects of ayahuasca on REFE. Seventeen healthy...